The Schizophrenia Research Team of University of Miami, Department of
Psychiatry is conducting research with patients diagnosed with
Schizophrenia or Schizoaffective Disorder
If you know of any individual who fits the following criteria, please contac
theSchizophrenia Research Office at 305-355-8186 or Joe Gorrin at 786-416-2207
Medication and cognitive remediation available to eligible participants.
Participants will be compensated.
Ѓ TENETS : Patients 18-65 years old with a diagnosis of Schizophrenia or schizoaffective disorder. If not already on Lurasidone, will be stabilized on Lurasidone for 8 weeks then randomized on to cognitive remediation program or control. If already on Lurasidone, patient will skip stabilization phase and start working directly with cognitive remediation program.
Ѓ e-CAeSAR: Computer-based cognitive remediation. Patient will stay on their current psychiatric treatment. No medication provided by study. Patients at least 18 years old with diagnosis of Schizophrenia. Clinically stable for the last 8 weeks. They must be maintained on antipsychotics and/or other concomitant psychotropic treatment for at least 6 weeks. No behaviors suggesting potential danger to self or others.
Ѓ ARRIVE (Aripiprazole IM): Patients 18-65 years old with diagnosis of Schizophrenia. Prior oral antipsychotic treatment for 7 months. Current treatment with oral Aripiprazole or wish to change antipsychotic medication is desirable. No behaviors suggesting potential danger to self or others.
Ѓ PRIDE: Patients 18-65 years old with a diagnosis of Schizophrenia, currently on one oral antipsychotic medication. Must have had 2 arrests with incarceration and the last release occurring within the past 90 days. In your opinion, may benefit from change in their antipsychotic treatment. Will be randomized on either paliperidone palmitate or one of seven oral antipsychotics. Cannot have history of allergic reaction to Risperidone. No behaviors suggesting potential danger to self or others.